Sponsor	Phase
VA Office of Research and Development
US Department of Veterans Affairs

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	085771-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 30, 2026

ecutive summary: Hydralazine, hydrochlorothiazide, and reserpine is a legacy fixed-dose antihypertensive combination with negligible current commercial relevance. The product category was displaced by safer, more flexible therapies, including ACE inhibitors, angiotensin receptor blockers, calcium-channel blockers, beta blockers, and modern thiazide regimens. No meaningful current revenue stream, active innovation cycle, or material patent barrier is publicly associated with the combination. Market value is limited to historical sales, occasional legacy prescriptions, and potential compounding or substitute-product demand.

Hydralazine, Hydrochlorothiazide With Reserpine Market Dynamics and Financial Trajectory

What is hydralazine, hydrochlorothiazide with reserpine?

The product combines three antihypertensive mechanisms:

Component	Pharmacologic class	Primary effect
Hydralazine	Direct arteriolar vasodilator	Reduces systemic vascular resistance
Hydrochlorothiazide	Thiazide diuretic	Promotes sodium and fluid excretion
Reserpine	Sympatholytic agent	Depletes catecholamines from peripheral nerve terminals

The combination was developed for hypertension treatment before modern multidrug regimens became standard. Hydralazine provided arterial dilation, hydrochlorothiazide reduced volume, and reserpine lowered sympathetic activity.

The clinical rationale has weakened substantially. Reserpine has a long adverse-effect profile, including depression, sedation, nasal congestion, gastrointestinal effects, bradycardia, and orthostatic hypotension. Hydralazine can cause tachycardia, fluid retention, headache, and, at higher cumulative exposure, a lupus-like syndrome. Hydrochlorothiazide remains widely used, but is usually prescribed as an individual component or with contemporary agents. [1][2]

Historical products included combinations marketed under names such as Ser-Ap-Es and related legacy formulations. Exact strengths and marketing rights varied by manufacturer and period. Product-level commercial activity has declined as prescribers moved toward titratable, guideline-preferred therapies.

What is the FDA regulatory status of the combination?

The combination is a legacy antihypertensive product rather than a current growth product in the FDA-regulated prescription market.

FDA regulatory status must be separated into three categories:

Whether a specific branded or generic product has an active application.
Whether a product is listed in the FDA Orange Book.
Whether individual ingredients remain available in other formulations.

Hydralazine and hydrochlorothiazide remain established active ingredients. Reserpine has also remained recognized pharmacologically, but its use is limited. The continued availability of the individual ingredients does not establish that the three-drug combination has an actively marketed FDA-approved product.

The FDA Orange Book identifies approved drug applications and relevant patent or exclusivity information. Legacy combination products that are no longer marketed may not appear as active commercial products, even if historical approvals or archived labeling remain accessible. [3] FDA’s National Drug Code Directory and Drugs@FDA records are therefore more relevant for confirming current product status than historical brand references alone. [4][5]

What patents protect hydralazine, hydrochlorothiazide with reserpine?

No material current patent estate is associated with the active ingredients as a combination.

The relevant intellectual-property position is summarized below:

IP category	Current commercial significance
Compound patents	Expired for hydralazine, hydrochlorothiazide, and reserpine
Original combination patents	Expired or commercially irrelevant because of age
Formulation patents	No known active, commercially significant formulation estate
Method-of-use patents	No material current exclusivity identified
Manufacturing patents	Unlikely to block ordinary production of the individual compounds
Orange Book patents	No active patent position generally associated with the legacy combination
Regulatory exclusivity	No current new-drug or biologic exclusivity pathway

The combination predates the modern patent lifecycle for most pharmaceutical products. Any original composition or formulation rights would have expired decades ago. The absence of a current patent barrier allows manufacturers, compounders, or suppliers to produce the individual ingredients subject to applicable FDA, state, quality, and manufacturing requirements.

Patent risk is therefore not the central commercial issue. The principal barriers are demand, product availability, manufacturing economics, regulatory maintenance, and clinical preference.

When does hydralazine, hydrochlorothiazide with reserpine lose exclusivity?

The combination lost meaningful exclusivity many years ago.

An exact patent expiration date cannot be assigned reliably without identifying the original sponsor, formulation, jurisdiction, filing history, and patent family. Legacy combination brands were often marketed under multiple licenses and product registrations, and their historical patent records may not map cleanly to a single modern Orange Book entry.

The commercial conclusion is clear:

Any original United States patent protection has expired.
No Hatch-Waxman exclusivity appears to provide current market protection.
A Paragraph IV challenge would have little practical value unless directed at a newly approved formulation or a separate modern product.
A new manufacturer would not face an originator-controlled patent wall for the historical active-ingredient combination.

How many patents cover the combination today?

No material active United States patent portfolio is publicly associated with the legacy three-drug combination.

The number of relevant active patents is effectively zero for ordinary commercial analysis. This does not exclude unrelated patents covering a manufacturing process, a particular dosage form, packaging, impurity profile, or newly engineered delivery system. Such rights would need to claim a specific product or process and would not restore exclusivity to the historical combination itself.

The patent estate is therefore weak on every major commercial dimension:

Patent-strength factor	Assessment
Remaining term	None of material commercial value
Claim breadth	Historical claims are expired
Product differentiation	Low
Formulation protection	No significant current position
Litigation leverage	Minimal
Licensing leverage	Minimal
Generic entry barrier	None based on composition patents

What formulations are protected by patents?

No current formulation category is known to provide meaningful exclusivity for hydralazine, hydrochlorothiazide, and reserpine together.

A manufacturer could theoretically develop an extended-release tablet, multiparticulate formulation, orally disintegrating tablet, or other delivery system. A genuinely novel formulation could support a new patent application if it met novelty, non-obviousness, written-description, and enablement requirements. Regulatory exclusivity would depend on the approval pathway and the clinical or technical attributes of the product.

A new formulation would face a difficult commercial case. The product would need to demonstrate a meaningful benefit over separate generic agents, such as improved adherence, lower adverse effects, or a clinically useful pharmacokinetic profile. Reserpine’s tolerability limitations would remain a central development issue.

What method-of-use patents cover the product?

No material method-of-use patent position is associated with the historical indication of treating hypertension with the three-drug combination.

The therapeutic use is longstanding and would generally be vulnerable to prior-art objections. A new method-of-use claim might target a narrowly defined population, dosing strategy, or clinical setting, but such a claim would require strong clinical support and would not necessarily create broad market protection.

Method-of-use enforcement would also be difficult because physicians could prescribe the ingredients separately. A manufacturer would need to establish that the claimed regimen, rather than the individual components, has a legally protected and commercially meaningful use.

Which companies are challenging the product?

No significant current Paragraph IV or patent litigation campaign is associated with the combination.

The likely competitive activity is substitution rather than litigation. Manufacturers compete through:

Availability of hydralazine tablets and injection products.
Availability of hydrochlorothiazide tablets and combination products.
Limited reserpine supply.
Contract manufacturing and pharmacy-compounding capacity.
Hospital and institutional purchasing agreements.
Generic pricing and wholesaler access.

Because the relevant active ingredients are old and largely generic, an ANDA sponsor would have little economic incentive to challenge an originator patent. The more likely route would be approval or marketing of the ingredients separately, where the regulatory and commercial burden is more manageable.

What is the Orange Book status of hydralazine, hydrochlorothiazide with reserpine?

The historical combination does not have the profile of a currently protected Orange Book product.

Orange Book relevance would depend on an active approved application and listed patents. A legacy brand may have historical FDA documentation without having a currently marketed, patent-protected product. The Orange Book should therefore be interpreted together with current FDA approval records, discontinued-product information, and National Drug Code data. [3][4]

For market analysis, the expected Orange Book conclusion is:

Question	Assessment
Active listed patent estate	No material estate identified
New chemical entity exclusivity	Expired
Pediatric exclusivity	Not commercially relevant
Orphan exclusivity	Not applicable
Current brand protection	None of material significance
Paragraph IV exposure	No active target of consequence

What patent litigation affects the combination?

No material current patent litigation is known to affect the three-drug combination.

Historical disputes, if any, would have little bearing on present market access because the relevant patent terms have expired. The more relevant legal issues are regulatory and commercial:

Whether a proposed product is considered a new drug requiring an approved application.
Whether a compounding pharmacy satisfies applicable federal and state requirements.
Whether manufacturing occurs under current good manufacturing practice standards.
Whether promotional claims are consistent with the approved labeling.
Whether a product is lawfully marketed after discontinuation of the historical brand.

FDA’s discontinued-drug framework matters because a discontinued product may have been withdrawn for commercial reasons, safety reasons, or other reasons. Those categories have different implications for future applicants. [5]

What is the financial trajectory of the product?

The financial trajectory is a long-term decline from historical branded sales to marginal or negligible direct revenue.

The product’s commercial decline reflects four factors:

Reserpine fell out of favor because of tolerability and safety concerns.
Fixed-dose combinations reduced physicians’ ability to adjust individual components.
Newer antihypertensive classes offered stronger evidence, simpler dosing, and broader guideline support.
The individual ingredients became inexpensive generic products.

Historical sales for the exact three-drug combination are not separately disclosed in major public company filings. The product was part of a broader cardiovascular portfolio, and revenue was generally reported at the company or therapeutic-area level rather than by individual legacy formulation.

The financial profile can be characterized as follows:

Period	Commercial trajectory
Initial launch period	Branded prescription product with differentiated combination therapy
Generic expansion	Price erosion and multiple substitute products
Modern guideline era	Prescribing contraction and declining manufacturer investment
Current period	Niche, legacy, or discontinued-product economics
Forward outlook	No credible volume or pricing growth without a redesigned product

Revenue exposure for a current manufacturer would be low unless the company controls a scarce supply source or serves a specialized institutional or compounding channel. Gross margins would likely be constrained by small production runs, regulatory overhead, quality testing, distribution fees, and uncertain demand.

How does the combination compare with modern antihypertensive drugs?

The three-drug combination is commercially disadvantaged against nearly every standard modern treatment pathway.

Therapy	Current clinical position	Commercial advantage
ACE inhibitor plus calcium-channel blocker	Common guideline-supported regimen	Strong evidence and broad generic supply
ARB plus thiazide	Widely used	Better tolerability than reserpine-based therapy
Calcium-channel blocker	First-line option	Simple dosing and strong generic competition
Beta blocker combinations	Used selectively	Established role in specific cardiovascular conditions
Hydralazine plus nitrate	Used in selected heart-failure populations	Defined niche indication
Hydralazine/HCTZ/reserpine	Legacy approach	Limited flexibility and poor contemporary positioning

Hydrochlorothiazide remains commercially relevant as an individual generic. Hydralazine retains clinical use in selected settings, including severe hypertension and certain pregnancy-related or heart-failure regimens. Reserpine has the weakest commercial position of the three ingredients.

The combination has no clear advantage in adherence, safety, outcomes, or cost over prescribing the components separately. A fixed-dose product could reduce pill burden, but its inclusion of reserpine limits adoption.

What generic entry risks exist?

Generic entry risk is not the main issue because effective generic entry has already occurred at the ingredient level and historical combination exclusivity has expired.

A new entrant would face four practical risks:

Low and uncertain demand.
Limited wholesaler and pharmacy stocking.
Ingredient-sourcing problems, particularly for reserpine.
Regulatory costs that exceed expected sales.

A manufacturer could also encounter market withdrawal risk. If annual volume is low, a single supplier interruption could make the product commercially unavailable without creating an attractive opportunity for competitors.

The most plausible generic-launch scenario would involve separate tablets rather than revival of the three-drug fixed-dose combination. A company could supply hydralazine and hydrochlorothiazide, while reserpine would remain a niche or special-order ingredient.

How strong is the patent estate for the product?

The patent estate is commercially weak.

The product has no meaningful remaining exclusivity, no obvious licensing asset, and no credible litigation moat. Its value would come from supply reliability, regulatory execution, and distribution rather than intellectual property.

A new entrant seeking to commercialize the combination would likely prioritize:

Confirming whether an active FDA-approved reference product exists.
Establishing the appropriate application pathway.
Demonstrating pharmaceutical equivalence and bioequivalence where required.
Securing stable sources for all three active ingredients.
Assessing the market for institutional, specialty, or compounded supply.
Avoiding unnecessary investment in a broad commercial launch.

What licensing deals involve the combination?

No material current licensing transactions are publicly associated with hydralazine, hydrochlorothiazide, and reserpine.

The historical brands may have involved licenses, corporate acquisitions, or distribution arrangements, but these relationships do not create current strategic value unless they include active approvals, manufacturing rights, trademarks, or supply contracts.

A modern licensing transaction would be commercially difficult to justify without one of the following:

A novel delivery technology.
A documented adherence or safety benefit.
A controlled-release formulation.
A supply agreement for an underserved market.
A regulatory approval in a jurisdiction with limited alternatives.

Without such differentiation, a license would transfer a low-growth generic asset rather than a defensible pharmaceutical franchise.

What geographic markets still have demand?

Demand is likely fragmented and concentrated in markets where older antihypertensive products remain available, inexpensive, or embedded in institutional formularies.

Potential channels include:

Selected low- and middle-income markets.
Hospital formularies with legacy purchasing patterns.
Long-term-care facilities.
Specialty pharmacies.
Extemporaneous-compounding pharmacies.
Markets with limited access to newer antihypertensive combinations.

United States demand is likely small. European and other developed-market demand is also constrained by treatment guidelines and the availability of newer low-cost generics. Geographic opportunity would depend more on local registration status and supply continuity than on patent rights.

What manufacturing and IP barriers exist?

The principal barriers are manufacturing and regulatory economics, not IP.

Reserpine requires reliable sourcing, validated analytical methods, impurity controls, and appropriate stability data. A three-active-ingredient product also creates greater formulation and quality-control complexity than a single-ingredient tablet. The manufacturer must demonstrate consistent content uniformity, dissolution, stability, and packaging performance.

Manufacturing barriers include:

Multi-ingredient blending and content uniformity.
Stability of all active ingredients in one dosage form.
Validation of analytical methods.
Small-batch production economics.
Supplier qualification.
Pharmacovigilance for a legacy product with limited contemporary use.
Compliance with current good manufacturing practice.

These barriers can prevent entry even when patents do not.

Key takeaways

Hydralazine, hydrochlorothiazide, and reserpine is a legacy antihypertensive combination with minimal current commercial significance.
The active ingredients are old and lack meaningful current composition-patent protection.
No material Orange Book exclusivity or Paragraph IV litigation target is associated with the historical combination.
Hydrochlorothiazide and hydralazine remain commercially available as individual generic ingredients; reserpine has limited demand.
Reserpine’s tolerability profile is the principal clinical weakness.
Modern antihypertensive regimens offer better flexibility, evidence, and market acceptance.
Exact product-level revenue is not separately disclosed in public filings.
Any current value would depend on niche supply, institutional demand, or a differentiated reformulation.
The forward financial trajectory is flat to declining, with no obvious basis for volume growth or pricing power.

FAQs about hydralazine, hydrochlorothiazide, and reserpine

Is Ser-Ap-Es still marketed in the United States?

Ser-Ap-Es is a historical brand associated with the three-drug antihypertensive combination. It does not have the profile of a broadly marketed current U.S. product. Current availability must be distinguished from historical labeling and archived brand references.

Can a pharmacy still compound hydralazine, hydrochlorothiazide, and reserpine?

A pharmacy may be able to compound a preparation only under applicable federal and state requirements and subject to ingredient availability. Compounding does not establish FDA approval or broad commercial availability.

Is reserpine still used for high blood pressure?

Reserpine is rarely used compared with modern antihypertensive classes. Its adverse-effect profile and the availability of better-tolerated alternatives have sharply reduced prescribing.

Does hydrochlorothiazide provide commercial value to this combination?

Hydrochlorothiazide remains commercially valuable as an individual generic and as a component of many modern fixed-dose products. That value does not transfer to the legacy three-drug combination.

Could a new extended-release version obtain patent protection?

A genuinely novel extended-release or other delivery system could potentially receive patent protection if it met U.S. patentability standards. Commercial success would require a clear clinical or adherence advantage over separate generic tablets and would still face the safety and adoption limitations associated with reserpine.

References

U.S. National Library of Medicine. (n.d.). DailyMed: Hydralazine hydrochloride, hydrochlorothiazide, and reserpine drug labeling. https://dailymed.nlm.nih.gov/
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). National Drug Code Directory and discontinued drug products. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms/ ರಾಷ್ಟ್ರೀಯ

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	1
Patent Applications:	1
DailyMed Link:	HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE at DailyMed

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE Drug Patent Profile

When do Hydralazine, Hydrochlorothiazide W/ Reserpine patents expire, and when can generic versions of Hydralazine, Hydrochlorothiazide W/ Reserpine launch?

AI Deep Research

Questions you can ask:

Summary for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

Recent Clinical Trials for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

US Patents and Regulatory Information for HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE